Chemotherapy versus Combined Chemoradiotherapy: Survival Patterns among Elderly Patients with Limited Stage Small Cell Lung Cancer

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Geriatric Oncology
Radiation Oncology
Presenter Sara Abdulaziz
Citation Annals of Oncology (2018) 29 (suppl_9): ix139-ix142. 10.1093/annonc/mdy445
Authors S. Abdulaziz
  • Medical Student, faculty of medecine suez canal university, 41511 - Ismailia/EG



Twenty-five percent of patients with Small Cell Lung Cancer (SCLC) are diagnosed in their Limited Stage (LS). Due to the potential risk of toxicity of using radiotherapy in the elderly, chemotherapy alone is used as the standard treatment protocol. Nowadays as the life expectancy is increasing, we have to improve the quality of life and survival rate of elderly patients. Therefore we carried out this study so as to compare the difference of survival rate among the elderly people with LS-SCLC treated with chemotherapy alone versus chemoradiotherapy.


Out of 1709 elderly patients with LS-SCLC diagnosed from 2010 to 2013, A number of 1248 (73%) received combined chemotherapy and radiotherapy while 461 (27%) received chemotherapy alone as analysed using Surveillance, Epidemiology, and End Results Database. Patient's demographics is also analysed.


The overall 2-year survival rates of elderly patients with LS-SCLC treated with chemotherapy alone versus combined chemoradiotherapy were 16.4% and 38.4% respectively (p value <0.001), which signifies better outcomes with chemoradiotherapy. Subgroup analysis by sex showed better outcomes with chemoradiotherapy in females than males, also subgroup analysis by age showed better outcomes with chemoradiotherapy in those aged from 65 to 69 years old.Table: 460P

VariablesSurvival of patients Chemoradiation ChemotherapyP value
Sex Male Female34.9% 14.8% 41.7% 17.6%0.034*
Age 65-69 70-74 75-79 80-84 85+41.9% 19.1% 41.2% 16.6% 31.6% 14.0% 31.5% 19.4% 19.2% 0.0%<0.0001**
Race White Black38.2% 17.4% 37.8% 12.7%0.658
Primary site Upper lobe Middle lobe Lower lobe38.8% 17.2% 28.7% 12.4% 39.8% 15.8%0.312

Highly significant P-value ≤ 0.001, in patients receiving chemoradiation.


Significant p-value >0.05, in patients receiving chemoradiation.


The addition of radiotherapy to chemotherapy in the treatment of elderly people having LS-SCLC has improved the overall 2-year survival rate when compared to treatment with chemotherapy alone. Further studies should be carried out to identify the benefits and risks of adding radiotherapy to the treatment of the elderly.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Faculty of Medicine, Suez Canal University.


Has not received any funding.


The author has declared no conflicts of interest.